Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Characteristic symptoms of inflammatory rheumatic diseases].
Mucke J, Sewerin P, Schneider M, Schulze-Koops H. Mucke J, et al. Among authors: schneider m. MMW Fortschr Med. 2020 Feb;162(2):35-39. doi: 10.1007/s15006-020-0103-x. MMW Fortschr Med. 2020. PMID: 32016765 Review. German. No abstract available.
[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].
Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, Holle J, Hoyer BF, Iking-Konert C, Krause A, Krüger K, Krusche M, Leipe J, Lorenz HM, Moosig F, Schmale-Grede R, Schneider M, Strangfeld A, Voll R, Voormann A, Wagner U, Schulze-Koops H. Specker C, et al. Among authors: schneider m. Z Rheumatol. 2021 Aug;80(6):570-587. doi: 10.1007/s00393-021-01056-6. Z Rheumatol. 2021. PMID: 34309739 Free PMC article. Review. German. No abstract available.
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.
Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, Holle J, Hoyer BF, Iking-Konert C, Krause A, Krüger K, Krusche M, Leipe J, Lorenz HM, Moosig F, Schmale-Grede R, Schneider M, Strangfeld A, Voll R, Voormann A, Wagner U, Schulze-Koops H. Specker C, et al. Among authors: schneider m. Z Rheumatol. 2021 Dec;80(Suppl 2):33-48. doi: 10.1007/s00393-021-01055-7. Epub 2021 Sep 7. Z Rheumatol. 2021. PMID: 34491403 Free PMC article. Review. No abstract available.
[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020].
Schulze-Koops H, Iking-Konert C, Leipe J, Hoyer BF, Holle J, Moosig F, Aries P, Burmester G, Fiehn C, Krause A, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wagner U, Krüger K, Specker C; Kommission Pharmakotherapie; Vorstand der Deutschen Gesellschaft für Rheumatologie. Schulze-Koops H, et al. Among authors: schneider m. Z Rheumatol. 2020 Sep;79(7):679-685. doi: 10.1007/s00393-020-00851-x. Z Rheumatol. 2020. PMID: 32757030 Free PMC article. Review. German.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Baraliakos X, et al. Among authors: schneider m. J Rheumatol. 2007 Mar;34(3):510-5. Epub 2007 Feb 1. J Rheumatol. 2007. PMID: 17299842 Clinical Trial.
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J. Baraliakos X, et al. Among authors: schneider m. Rheumatology (Oxford). 2011 Sep;50(9):1690-9. doi: 10.1093/rheumatology/ker194. Epub 2011 Jun 14. Rheumatology (Oxford). 2011. PMID: 21672969
S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes - Teil 1: Klassifikation, Diagnostik, Prävention und Aktivitätsscores.
Worm M, Zidane M, Eisert L, Fischer-Betz R, Foeldvari I, Günther C, Iking-Konert C, Kreuter A, Müller-Ladner U, Nast A, Ochsendorf F, Schneider M, Sticherling M, Tenbrock K, Wenzel J, Kuhn A. Worm M, et al. Among authors: schneider m. J Dtsch Dermatol Ges. 2021 Aug;19(8):1236-1248. doi: 10.1111/ddg.14492_g. J Dtsch Dermatol Ges. 2021. PMID: 34390147 German. No abstract available.
7,264 results